Click here to read the articles and view the interactive digital edition

Pharmaceutical Commerce - November 2025

Cencora executive Heather Zenk discusses how innovations in cold chain, data visibility, and sustainability strategies are transforming the drug delivery process.

Building Resilient, Sustainable Pharma Supply Chains

From patent cliffs and government price controls, to self-pay models and staff-model HMOs, a look at the forces that could deflate the bubble—and those factors likely to keep it afloat a while longer.

Popping the Gross-to-Net Bubble, Part VI: The Future of Pharmaceutical Pricing

Advice for pharma distributors and dispensers on what they should do now in order to solidify a secure supply chain.

DSCSA Compliance: Milestones, More Deadlines—and the Road Ahead

. He can be reached at nsaraceno@mjhlifesciences.com.

Articles

Brett Casper explores the marketplace complexities that manufacturers face regularly. 

Asembia 2025: Navigating the Product Commercialization Process

Videos

Tiara Green, president, Accessia Health, highlights key themes from the upcoming discussion on how health equity, literacy, and social determinants are reshaping patient care—especially for those with chronic and rare conditions.

Asembia 2025: Bridging Health Gaps Through Equity and Education

A session dives into the trends surrounding specialty drugs and therapies, along with providing an overview of the drug development landscape. 

Asembia 2025: The Specialty Pharma Pipeline

Blake Powers, CEO, Medigi, discusses how face-to-face collaboration and streamlined commercialization strategies are helping life sciences companies deliver therapies more efficiently to patients.

Asembia 2025: The Role of Face-to-Face Connection in Pharma Commercialization

In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Paul Levesque, CEO of Theratechnologies, describes the uneasiness behind regulatory complications. 

Why Distractions Are Detrimental to Business

Pharma Pulse 4/28/25: US Pharma Tariffs Would Raise US Drug Costs by $51 Billion Annually, Report Finds, How the Tariffs Expose Vulnerabilities in the Pharma Pipeline

The company’s branded form of nadofaragene firadenovec-vncg will also be produced at a hub in Parsippany, NJ. 

FDA Approves Additional Manufacturing Plant for Ferring’s Adstiladrin

Podcasts

Claire Riches highlights inefficiencies in the current drug approval process, while outlining the role of payers and insurers in shifting toward data-driven approval framework. 

Fast-Tracking the Future

In the third part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Paul Levesque, CEO of Theratechnologies, explains what the mindset be for companies who are just starting the reshoring process.

Will Moving Drug Production to the United States Help or Hurt Patients?

Pharma Pulse 4/25/25: Roche in ‘Very, Very Good Position’ To Weather Trump Tariffs but M&A May Suffer, Thermo Fisher to Invest Addlitional $2 Billion In US To Boost Manufacturing

Featured Content

Pharmaceutical Commerce - November 2025

Building Resilient, Sustainable Pharma Supply Chains

Popping the Gross-to-Net Bubble, Part VI: The Future of Pharmaceutical Pricing

DSCSA Compliance: Milestones, More Deadlines—and the Road Ahead